Literature DB >> 2070080

Establishment and characterization of a new human leukemia cell line derived from M4E0.

K Yanagisawa1, T Horiuchi, S Fujita.   

Abstract

A new human leukemia cell line, designated as ME-1, was established from the peripheral blood leukemia cells of a patient with acute myelomonocytic leukemia with eosinophilia (M4E0). This cell line has the characteristic chromosome abnormality of M4E0, inv(16) (p13q22). When cultured in RPMI 1640 medium containing 10% fetal calf serum, ME-1 cells were monoblastoid, but with the addition of cytokines such as interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4, or medium conditioned by phytohemagglutinin-stimulated human peripheral leukocytes (PHA-LCM), the cells exhibited differentiation to macrophage-like cells. PHA-LCM also promoted eosinophilic-lineage differentiation of this cell line, although IL-5 did not do so. To elucidate the mechanism of proliferation and differentiation of ME-1 cells, we studied the effect of a potent inhibitor of protein kinase C, 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine (H-7), on colony formation of ME-1 cells. H-7 inhibited colony formation of ME-1 cells by IL-3 or GM-CSF dose dependently, but had little inhibitory effect on colony formation by IL-4. These results indicate that the proliferation and differentiation of ME-1 cells by IL-3 or GM-CSF were related to the activation of protein kinase C, while those by IL-4 involved other regulatory systems. ME-1 cells should be useful for studying the pathogenesis of M4E0 and the mechanisms of proliferation and differentiation of leukemic and normal progenitors by cytokines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Authors:  Y Kanno; T Kanno; C Sakakura; S C Bae; Y Ito
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells.

Authors:  Y W Zhang; S C Bae; G Huang; Y X Fu; J Lu; M Y Ahn; Y Kanno; T Kanno; Y Ito
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.

Authors:  Lisa E Richter; Yiqian Wang; Michelle E Becker; Rachel A Coburn; Jacob T Williams; Catalina Amador; R Katherine Hyde
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

5.  CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.

Authors:  A Mandoli; A A Singh; P W T C Jansen; A T J Wierenga; H Riahi; G Franci; K Prange; S Saeed; E Vellenga; M Vermeulen; H G Stunnenberg; J H A Martens
Journal:  Leukemia       Date:  2013-09-04       Impact factor: 11.528

6.  Detection of cyclin D1 overexpression by real-time reverse-transcriptase-mediated quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma.

Authors:  R Suzuki; K Takemura; M Tsutsumi; S Nakamura; N Hamajima; M Seto
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  miR-139-5p controls translation in myeloid leukemia through EIF4G2.

Authors:  S Emmrich; F Engeland; M El-Khatib; K Henke; A Obulkasim; J Schöning; J E Katsman-Kuipers; C Michel Zwaan; A Pich; J Stary; A Baruchel; V de Haas; D Reinhardt; M Fornerod; M M van den Heuvel-Eibrink; J H Klusmann
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

8.  Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.

Authors:  ShriHari S Kadkol; Annette Bruno; Carol Dodge; Valerie Lindgren; Farhad Ravandi
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

9.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Authors:  Lea Cunningham; Steven Finckbeiner; R Katherine Hyde; Noel Southall; Juan Marugan; Venkat R K Yedavalli; Seameen Jean Dehdashti; William C Reinhold; Lemlem Alemu; Ling Zhao; Jing-Ruey Joanna Yeh; Raman Sood; Yves Pommier; Christopher P Austin; Kuan-Teh Jeang; Wei Zheng; Paul Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-21       Impact factor: 11.205

10.  Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.

Authors:  Rui Wang; Lijuan Xia; Janice Gabrilove; Samuel Waxman; Yongkui Jing
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.